M Dror Michaelson1, Chen Hu2, Huong T Pham3, Douglas M Dahl4, Chin Lee-Wu4, Gregory P Swanson5, Jacqueline Vuky3, R Jeffrey Lee6, Luis Souhami7, Brian Chang8, Asha George9, Howard Sandler10, William Shipley4. 1. Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address: dmichaelson1@partners.org. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania; Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Virginia Mason CCOP, Seattle, Washington. 4. Massachusetts General Hospital Cancer Center, Boston, Massachusetts. 5. University of Texas at San Antonio, San Antonio, Texas. 6. Intermountain Medical Center, Murray, Utah. 7. McGill University, Montréal, Quebec. 8. Parkview Cancer Center, Parkview Hospital, Fort Wayne, Indiana. 9. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. 10. Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
PURPOSE: Bladder preservation therapy is an effective treatment for muscle-invasive urothelial carcinoma (UC). In this study we treated noncystectomy candidates with daily radiation and weekly paclitaxel for 7 weeks. Patients whose tumors showed her2/neu overexpression were additionally treated with weekly trastuzumab. METHODS AND MATERIALS: Sixty-eight evaluable patients were treated with radiation therapy and either paclitaxel + trastuzumab (group 1) or paclitaxel alone (group 2). Groups were assigned on the basis of her2/neu immunohistochemistry results. Patients received 1.8-Gy fractions to a total dose of 64.8 Gy. The primary endpoint of the study was treatment-related toxicity, and secondary endpoints included complete response (CR) rate, protocol completion rate, and survival. RESULTS: A total of 20 evaluable patients were treated in group 1 and 46 patients in group 2. Acute treatment-related adverse events (AEs) were observed in 7 of 20 patients in group 1 (35%) and 14 of 46 patients in group 2 (30.4%). Protocol therapy was completed by 60% (group 1) and 74% (group 2) of patients. Most incompletions were due to toxicity, and the majority of AEs were gastrointestinal, including 1 grade 5 AE (group 1). Two other deaths (both in group 2) were unrelated to protocol therapy. No unexpected cardiac, hematologic, or other toxicities were observed. The CR rate at 1 year was 72% for group 1 and 68% for group 2. CONCLUSIONS: In patients with muscle-invasive UC who are not candidates for cystectomy, daily radiation combined with paclitaxel is an effective treatment strategy with a high completion rate and moderate toxicity. In patients with her2/neu-positive tumors, a group generally considered to have worse outcomes, the addition of trastuzumab appears to result in comparable efficacy and toxicity. Further biomarker-driven trials should be undertaken in advancing treatment of this challenging disease.
PURPOSE: Bladder preservation therapy is an effective treatment for muscle-invasive urothelial carcinoma (UC). In this study we treated noncystectomy candidates with daily radiation and weekly paclitaxel for 7 weeks. Patients whose tumors showed her2/neu overexpression were additionally treated with weekly trastuzumab. METHODS AND MATERIALS: Sixty-eight evaluable patients were treated with radiation therapy and either paclitaxel + trastuzumab (group 1) or paclitaxel alone (group 2). Groups were assigned on the basis of her2/neu immunohistochemistry results. Patients received 1.8-Gy fractions to a total dose of 64.8 Gy. The primary endpoint of the study was treatment-related toxicity, and secondary endpoints included complete response (CR) rate, protocol completion rate, and survival. RESULTS: A total of 20 evaluable patients were treated in group 1 and 46 patients in group 2. Acute treatment-related adverse events (AEs) were observed in 7 of 20 patients in group 1 (35%) and 14 of 46 patients in group 2 (30.4%). Protocol therapy was completed by 60% (group 1) and 74% (group 2) of patients. Most incompletions were due to toxicity, and the majority of AEs were gastrointestinal, including 1 grade 5 AE (group 1). Two other deaths (both in group 2) were unrelated to protocol therapy. No unexpected cardiac, hematologic, or other toxicities were observed. The CR rate at 1 year was 72% for group 1 and 68% for group 2. CONCLUSIONS: In patients with muscle-invasive UC who are not candidates for cystectomy, daily radiation combined with paclitaxel is an effective treatment strategy with a high completion rate and moderate toxicity. In patients with her2/neu-positive tumors, a group generally considered to have worse outcomes, the addition of trastuzumab appears to result in comparable efficacy and toxicity. Further biomarker-driven trials should be undertaken in advancing treatment of this challenging disease.
Authors: Arnab Chakravarti; Kathryn Winter; Chin-Lee Wu; Donald Kaufman; Elizabeth Hammond; Matthew Parliament; William Tester; Michael Hagan; David Grignon; Niall Heney; Alan Pollack; Howard Sandler; William Shipley Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-01 Impact factor: 7.038
Authors: Nicholas D James; Syed A Hussain; Emma Hall; Peter Jenkins; Jean Tremlett; Christine Rawlings; Malcolm Crundwell; Bruce Sizer; Thiagarajan Sreenivasan; Carey Hendron; Rebecca Lewis; Rachel Waters; Robert A Huddart Journal: N Engl J Med Date: 2012-04-19 Impact factor: 91.245
Authors: K Sato; M Moriyama; S Mori; M Saito; T Watanuki; K Terada; E Okuhara; T Akiyama; K Toyoshima; T Yamamoto Journal: Cancer Date: 1992-11-15 Impact factor: 6.860
Authors: Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: P L Nguyen; P E Swanson; W Jaszcz; D M Aeppli; G Zhang; T P Singleton; S Ward; D Dykoski; J Harvey; G A Niehans Journal: Am J Clin Pathol Date: 1994-02 Impact factor: 2.493
Authors: Elliott Freudenburg; Iyla Bagheri; Sunay Srinivas; Ariza Martinez; Nagireddy Putluri; Zachary Klaassen; Ashish M Kamat; Badrinath R Konety; William Y Kim; Lars Dyrskjøt; David J McConkey; Stephen J Freedland; Peter C Black; Siamak Daneshmand; James W F Catto; Stephen B Williams Journal: Cancer Causes Control Date: 2022-06-14 Impact factor: 2.532
Authors: Yubing Tong; Jayaram K Udupa; Chuang Wang; Jerry Chen; Sriram Venigalla; Thomas J Guzzo; Ronac Mamtani; Brian C Baumann; John P Christodouleas; Drew A Torigian Journal: Adv Radiat Oncol Date: 2018-05-08